Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

AI-Driven Hip Exoskeleton Control for Diverse Users and Walking Tasks

10. november 2026 oppdatert av: Inseung Kang, Carnegie Mellon University

AI-Driven Hip Exoskeleton Control Framework That Rapidly Generalizes to a Broad Range of Users and Real-World Locomotor Tasks

The goal of this clinical trial is to evaluate the feasibility of a prototype artificial intelligence (AI)-based controller for a lightweight hip exoskeleton across a broad range of users, including healthy younger adults (18-39 years) and older adults (65 years and older). The main questions it aims to answer are:

  • Can the AI-based controller accurately estimate gait phase in real time across younger and older adults?
  • How does hip exoskeleton assistance change walking energy cost, mechanics, and muscle activity?

Researchers will compare walking with powered hip exoskeleton assistance to walking without the exoskeleton and walking while wearing the exoskeleton with no assistance (zero torque).

Participants will:

  • Complete a short screening and frailty assessment
  • Walk on a treadmill under different conditions with and without the hip exoskeleton during 2 to 5 lab visits
  • Wear motion capture markers, muscle activity (EMG) sensors, and a mask that measures breathing to estimate energy use

Studieoversikt

Status

Rekruttering

Detaljert beskrivelse

This study is funded by the National Institute of Biomedical Imaging and Bioengineering (R21EB037268) and conducted at the University of Texas at Austin in collaboration with Carnegie Mellon University. The CMU Hip Exoskeleton is a research prototype with powered hip joints for flexion and extension (peak torque 18 Nm, total weight 3.5 kg). Its controller uses joint angle and user-state estimates to command assistive torque, limited to less than 0.2 Nm/kg (at most about 30% of typical biological hip moments during walking), so it supplements rather than overrides the user's own muscle effort.

During each visit, participants walk on a force-instrumented treadmill at 1.25 m/s with safety harness and handrails. Researchers record whole-body motion capture, ground reaction forces, inertial measurement unit data, lower-limb electromyography, and metabolic energy expenditure via open-circuit indirect calorimetry. Walking conditions include no exoskeleton, exoskeleton worn with zero torque, and powered exoskeleton assistance. Outcomes will be compared across conditions and between younger and older adults using repeated-measures statistical analysis.

Studietype

Intervensjonell

Registrering (Antatt)

16

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Texas
      • Austin, Texas, Forente stater, 78712
        • Rekruttering
        • University of Texas at Austin
        • Ta kontakt med:
        • Ta kontakt med:
        • Hovedetterforsker:
          • Owen Beck, PhD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Age 18 to 39 years (younger adult group) or 65 years and older (older adult group)
  • Willing and able to provide informed consent
  • Able to walk independently without assistance
  • No known cardiovascular, metabolic, or renal disease, and no signs or symptoms suggestive of such disease
  • Cleared for light- to moderate-intensity exercise without the need for medical clearance under American College of Sports Medicine (ACSM) preparticipation screening guidelines

Exclusion Criteria:

  • Age 40 to 64 years
  • Leg surgery within the past 5 years
  • Orthopedic disability that could impair movement or limit participation in the exercise protocol
  • Neurologic disorder that may affect neuromuscular function or gait (e.g., stroke, Parkinson's disease, peripheral neuropathy, traumatic brain injury)
  • Known metabolic or cardiovascular disease (hypertension alone is not exclusionary), or requiring medical clearance under ACSM guidelines without having obtained it
  • Metal implants in the lower extremities, cardiac pacemaker, or other implanted electronic device
  • Pregnancy
  • History of seizure disorder or fainting (syncope)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Enhetens gjennomførbarhet
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Hip Exoskeleton Walking

Healthy younger adults (18-39 years) and older adults (65+ years) walk on an instrumented treadmill under multiple conditions across 2-5 lab visits: no exoskeleton, wearing the CMU Hip Exoskeleton with zero torque, and with powered assistance from the AI-driven hip exoskeleton controller (assistance limited to <0.2 Nm/kg). The primary objective is to evaluate real-time gait phase estimation accuracy of the prototype controller across users; metabolic cost, biomechanics, and muscle activity are recorded as secondary measures.

A lightweight (3.5 kg) research hip exoskeleton developed at Carnegie Mellon University with powered hip flexion/extension joints, a backpack-mounted computer and battery, and thigh and waist interfaces secured with straps. An AI-driven controller estimates the user's gait state from joint angle and wearable sensor data and commands assistive hip torque in real time, limited to <0.2 Nm/kg (peak device torque 18 Nm). Participants walk on a treadmill with powered assistance, with the device worn at zero torque, and without the device. The device was determined by the UT Austin IRB to be a non-significant risk device.

Andre navn:
  • CMU Hip Exoskeleton

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Gait Phase Estimation Error of the AI-Driven Hip Exoskeleton Controller
Tidsramme: Day 1

Root-mean-square error (RMSE) between the controller's real-time gait phase estimate and ground-truth gait phase derived from force-instrumented treadmill data during powered hip exoskeleton walking, reported as percent of the gait cycle (%). Used to evaluate feasibility of the prototype controller across younger and older adult users.

Day 1

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Net Metabolic Power During Powered Hip Exoskeleton Walking
Tidsramme: Day 1

Net metabolic power (W/kg), measured by open-circuit indirect calorimetry with resting value subtracted, during treadmill walking at 1.25 m/s with powered hip exoskeleton assistance.

Day 1
Peak Hip Joint Moment During Powered Hip Exoskeleton Walking
Tidsramme: Day 1

Peak biological hip extension moment (Nm/kg), computed from motion capture and force-instrumented treadmill data, during treadmill walking with powered hip exoskeleton assistance.

Day 1
Lower-Limb Muscle Activity During Powered Hip Exoskeleton Walking
Tidsramme: Day 1

Average electromyography (EMG) amplitude normalized to maximum voluntary contraction (%MVC), averaged across eight recorded lower-limb muscles, during treadmill walking with powered hip exoskeleton assistance.

Day 1

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Inseung Kang, PhD, Carnegie Mellon University

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

6. august 2026

Primær fullføring (Antatt)

31. august 2027

Studiet fullført (Antatt)

31. januar 2028

Datoer for studieregistrering

Først innsendt

3. november 2026

Først innsendt som oppfylte QC-kriteriene

10. november 2026

Først lagt ut (Faktiske)

16. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • STUDY2026_00000477
  • R21EB037268 (U.S. NIH-stipend/kontrakt)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

De-identified individual participant data underlying published results will be shared, including biomechanics (motion capture, ground reaction forces), electromyography, metabolic, and exoskeleton sensor/controller data, along with participant characteristics (age group, sex, height, mass). Identifiable information, including video recordings, will not be shared.

IPD-delingstidsramme

Data will be made available no later than the time of associated publication or the end of the award period, whichever comes first, and will remain available for at least 5 years.

Tilgangskriterier for IPD-deling

De-identified data and supporting information will be deposited in a public data repository and made openly available to researchers without restriction, subject to the repository's terms of use.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • ANALYTIC_CODE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere